期刊
REVIEWS IN INORGANIC CHEMISTRY
卷 -, 期 -, 页码 -出版社
WALTER DE GRUYTER GMBH
DOI: 10.1515/revic-2023-0010
关键词
breast cancer; hormone receptor-positive (HR+); mechanism of action NAMI-A/KP1019; ruthenium; triple-negative breast cancer (TNBC)
This article reviews the inhibitory effects of polypyridine Ru(II) complexes on breast cancer cells and their potential as anticancer drug candidates due to their multi-targeting properties. It emphasizes the need for further research to determine the impact of these agents on the metastatic potential of breast cancer cells. The mechanism of action of Ru-based anticancer candidates NAMI-A and KP1019 during phase I clinical trials is discussed.
Breast cancer cells have long been inhibited by polypyridine Ru(II) complexes, which are excellent antitumor agents. Due to their multi-targeting properties, this class of ruthenium complexes has received increasing attention as anticancer drug candidates approach to various cellular targets. The aim of this review is to give information about the ligands that were carefully chosen for ruthenium complexes. There has been a great deal of interest in using ruthenium-based complexes to treat breast cancer. Several species have shown potential as treatment candidates. However, further research is needed to determine how these agents affect the metastatic potential of breast cancer cells. The mechanism of action of Ru-based anticancer candidates NAMI-A and KP1019 during phase I clinical trials has been discussed. This article explains hormone-positive breast cancer and triple-negative breast-cancer treatment by using Ru complexes. Although platinum (Pt-based) anticancer medication is widely used in cancer treatment, a minor improvement has been seen and that is Platinum replaced with Ruthenium for its anticancer properties. We have also highlighted the best effective ruthenium-based complexes in treating T.N.B.C. (triple-negative breast cancer) here in this collection.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据